Comparative Pharmacology
Head-to-head clinical analysis: CEFTAZIDIME IN DEXTROSE CONTAINER versus VELOSEF 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAZIDIME IN DEXTROSE CONTAINER versus VELOSEF 125.
CEFTAZIDIME IN DEXTROSE CONTAINER vs VELOSEF '125'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
1-2 g intravenously every 8 hours.
500 mg orally every 6 hours for uncomplicated infections; 1 g orally every 6 hours for more severe infections.
None Documented
None Documented
1.9 hours (normal renal function); prolonged to 22-30 hours in ESRD
Terminal elimination half-life: 0.5-1.0 hour (normal renal function); prolonged to 10-20 hours in severe renal impairment (CrCl <10 mL/min)
Renal: 80-90% unchanged drug via glomerular filtration; biliary: <1%; fecal: <1%
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic